Bibliografía del artículo
1. Perez Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu 14(Pt 2):182-213, 1979.
2. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - Fact or fantasy. Hepatology 43(2):S82-88, 2006.
3. Yoshida EM, Ramji A, Chatur N, Davis JE, Owen DA. Regression of cirrhosis associated with hepatitis B e (HBe) antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy. Eur J Gastro & Hepatology 16:355-58, 2004.
4. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127:981-85, 1997.
5. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histology analysis with weight loss. Hepatology 39:1647-54, 2004.
6. Kral JG, Thug SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135:48-58, 2004.
7. Dienstag J, Goldin R, Heathcote, EJ, Hann HW, Woessner M, Stephenson Sl, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-117, 2003.
8. Yuen MF, Chow DHF, Tsui K, Wong CY, Yuen CH, Wong DKH, et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther 21:841-49, 2005.
9. Chan HLY, Leung NWY, Hui AY, Wong VWS, Liew CT, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-a2b and lamivudine with lamivudine alone. Ann Intern Med 142(4):240-50, 2005.
10. Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, et al. Reversibility of cirrhosis in chronic hepatitis B. Clinical Gastro and Hepatology 2:344-47, 2004.
11. Rizzetto M, Tassopoulos NC, Glodin RD, Esteban R, Santantonio T, Heathcote EJ, et al. Extended lamivudine treatment in patients with HBe-Ag-negative chronic hepatitis B. Journal of Hepatology 42:173-79, 2005.
12. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The Multivirc Group. Gastroenterology 116:378-86, 1999.
13. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517-24, 2000.
14. Poynard T, Mchutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-37, 2000.
15. Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Mahl TC, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Digestive Diseases and Sciences 48(7):1425-30, 2003.
16. Arima M, Terao H, Kashima K, Arita T, Nasu M, Nishizono A. Regression of liver fibrosis in case of chronic liver disease type C: Quantitative evaluation by using computed image analysis. Internal Medicine 43(10):902-910, 2004.